Repository
Publications
Identification of PRMT5 as a therapeutic target in cholangiocarcinomaElurbide J, Colyn L, Latasa MU, Uriarte I, Mariani S, Lopez-Pascual A, Valbuena E, Castello-Uribe B, Arnes-Benito R, Adan-Villaescusa E, Martinez-Perez LA, Azkargorta M, Elortza F, Wu H, Krawczyk M, Schneider KM, Sangro B, Aldrighetti L, Ratti F, Casadei Gardini A, Marin JJG, Amat I, Urman JM, Arechederra M, Martinez-Chantar ML, Trautwein C, Huch M, Cubero FJ, Berasain C, G Fernandez-Barrena M, Avila MA.
|
Quality of Life and Clinical Outcomes of Endosonography-Guided Biliary Drainage in Patients with Malignant Biliary Obstruction: A Single-Center, Prospective AnalysisKrupa Ł, Smyk W, Staron R, Niemiec E, Jadwisiak A, Milkiewicz P, Żorniak M, Krawczyk M
|
ASO Visual Abstract: Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Diseasevan Keulen AM, Buettner S, Olthof PB, Klümpen HJ, Erdmann JI, Izquierdo-Sanchez L, Banales JM, Goeppert B, Roessler S, Zieniewicz K, Lamarca A, Valle JW, La Casta A, Hoogwater FJH, Donadon M, Scheiter A, Marzioni M, Adeva J, Kiudeliene E, Fernández JMU, Vidili G, Mocan T, Fabris L, Krawczyk M, Folseraas T, Dopazo C, Detry O, Voiosu T, Scripcariu V, Biancaniello F, Braconi C, Macias RIR, Groot Koerkamp B.
|
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide populationRimini M, Fornaro L, Rizzato M, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim J, Abidoye O, Rapposelli I, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon H, Braconi C, Pirrone C, Casadei-Gardini A.
|
Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinomaXia C, Krawczyk M, Di C, Krupa Ł, Kruk B, Krawczyk P, Milkiewicz P, Bao H, He X, Liu D, Fan C, Nasser A, Lopens S, Ulrich Weiss F, Frost F, Schierack P, Roggenbuck D, Liu Y.
|